Pfizer

Grants will be awarded in support of programs for dermatologists and allergists on new and emerging AD therapies. Particular areas of interest include, but are not limited to, helping dermatologists and allergists stay current with newly emerging data for advanced therapies; providing dermatologists and allergists with an overview of the benefits and risk profile of new and emerging therapies such as JAK inhibitors for AD; and improving understanding among dermatologists and allergists of the role vaccination plays in the care of patients with AD, especially with the use of JAK inhibitors and other immunosuppressive agents. It is not Pfizer's intent to support clinical research projects or projects that evaluate the efficacy of therapeutic or diagnostic agents.

Eligible applicants include medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions; professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement. If a project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.